Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability study of synthetic THC chewing gum versus dronabinol capsules in healthy volunteers
NL-OMON49009Recruiting
- Sponsor
- AXIM Biotechnologies, Inc.
- Start
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of dronabinol and synthetic tetrahydrocannabinol in chemotherapy-induced nausea and vomiting (CINV) (3 arms), sponsored by AXIM Biotechnologies, Inc. Primary endpoints: THC plasma concentration after single dose administration of synthetic THC chewing gum and AUC0-inf of THC. Started Jan 2020; status: recruiting.
02
Drugs
dronabinolsynthetic tetrahydrocannabinol
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NL-OMON49009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49009.